Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.45 3.78% 12.35 1,296,064 14:00:25
Bid Price Offer Price High Price Low Price Open Price
12.20 12.50 12.35 11.90 11.90
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 11.03 -18.86 -21.30 10
Last Trade Time Trade Type Trade Size Trade Price Currency
16:28:41 O 671 12.23 GBX

Hvivo (HVO) Latest News

More Hvivo News
Hvivo Investors    Hvivo Takeover Rumours

Hvivo (HVO) Discussions and Chat

Hvivo Forums and Chat

Date Time Title Posts
04/12/202222:05hVIVO plc603
26/10/202207:49hVIVO plc2,750

Add a New Thread

Hvivo (HVO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hvivo trades in real-time

Hvivo (HVO) Top Chat Posts

Top Posts
Posted at 04/12/2022 08:20 by Hvivo Daily Update
Hvivo Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker HVO. The last closing price for Hvivo was 11.90p.
Hvivo Plc has a 4 week average price of 9.25p and a 12 week average price of 8.57p.
The 1 year high share price is 24.75p while the 1 year low share price is currently 8.57p.
There are currently 83,664,276 shares in issue and the average daily traded volume is 1,062,990 shares. The market capitalisation of Hvivo Plc is £10,332,538.09.
Posted at 22/11/2022 20:48 by garth
sikhthetech22 Nov '22 - 17:12 - 500 of 503
0 0 0
The share price is where it was only a few months ago. Since then it fell after the H1 results and no news since last week to justify the significant rise.


Sikh,

I think you might be looking at this through the wrong end.

From the end I'm looking at it through:

Decent results and another contract and the share price fell without justification. Nothing to justify the fall except wider market gravity. The share price is now normalising.

No other explanation needed.

Except that I would add that when I read Simon Thompson's piece I wondered about the timing of its release. I.e. was it timed to align with a point at which a known and long present line of stock was drying up?

That last bit is pure conjecture on my part though.

G.

Posted at 21/11/2022 18:32 by sikhthetech
Rivaldo,

"With £53m of of the forecast 2023 £56m revenues already covered per Finncap there must be a good chance that HVO will beat expectations next year."

Rampers were saying similar last year(then called Orph) for fy2022 revenue. It didn't make any difference, did it?. In fact the share price still continued on the downtrend as expectations were missed, as usual.
Why should it be any different this time?


The fact, as recent contract rns shows, is any new work will commence towards end of 2023 and revenue will be recognised in 2024, with some in 2023.

The fy2023 results probably announced in June 2024 (if they keep to same timetable as before), so 18months away and fy2024 in June 2025, so 2.5yrs away!!!!!




from 10th Nov:
" The study is expected to commence in Q3/Q4 2023, with the revenue being recognised in 2023 and 2024."

https://uk.advfn.com/stock-market/london/hvivo-HVO/share-news/hVIVO-PLC-GBP13-6m-RSV-antiviral-contract/89515966

Posted at 21/11/2022 16:01 by sikhthetech
Don't take my word for it, readers should check the performance and shares for themselves..

sikhthetech - 14 Nov 2022 - 12:51:46 - 226 of 302 hVIVO plc - HVO
1gw,

Why you haven't commented on trmr's dismal Q3 results? The share price crashed around 30% so far. That follows your usual performance, where your shares crash on facts/results.
Shameful.


Other shares performance as of couple months ago:
https://uk.advfn.com/cmn/fbb/thread.php3?id=49342172&from=4915&to=4915

Posted at 21/11/2022 15:24 by parob
Makes a huge difference once you break the trading range. Even Simon Thompson mentioned it in his buy recommendation: "It's also worth noting that the share price seems to have finally formed a base in the 9p to 10.6p trading range, having deflated from a bubble valuation during Covid-19 lockdowns when day traders sent the shares soaring way above their intrinsic value. A share price break-out above the top of that trading range would be a strong signal that the consolidation period is finally over. Buy."
Posted at 21/11/2022 13:14 by sikhthetech
Rivaldo,

"With £53m of of the forecast 2023 £56m revenues already covered per Finncap there must be a good chance that HVO will beat expectations next year."

Rampers were saying similar last year(when these were Orph) for fy2022 revenue. It didn't make any difference. In fact the share price still continued it downtrend as expectations were missed, as usual.

The fact, as recent contract rns shows, is any new work will commence towards end of 2023 and revenue will be recognised in 2024, with some in 2023.

The fy2023 results probably announced in June 2024 (if they keep to same timetable as before), so 18months away and fy2024 in June 2025, so 2.5yrs away!!!!!




from 10th Nov:
" The study is expected to commence in Q3/Q4 2023, with the revenue being recognised in 2023 and 2024."

https://uk.advfn.com/stock-market/london/hvivo-HVO/share-news/hVIVO-PLC-GBP13-6m-RSV-antiviral-contract/89515966




owenski - 10 Dec 2021 - 09:15:38 - 570 of 5589 OPEN ORPHAN
Next years guidance in the £50m region, margins expected to be improving to possibly 30 - 35%
Some Covid work is reckoned to be on top of that - quantity unknown at this stage.

80% of next years revenues already secured - how many companies are in that kind of sweet spot.

A further 4 to 5 influenza studies in contract negotiation - size between 4 to 12m
Malarial study being negotiated.
Other studies in the pipeline.
OO in a sweet spot with products to sell in a growing market.
Potential upside from spinouts still to come for free.


These are being pumped/dumped by the blnx(now trmr) gang. Look at trmr thread, no posts, yet it's busy here.

Posted at 21/11/2022 08:27 by parob
Yes Garth, it would have a big impact on the share price if another large contract is announced. And ST would love it.Well I have increased my personal exit target price over the weekend from 20p to 24p. Simon Thompson's conservative 19p + £30M (5p) for DIM and HVO's share of Imutex and PrEP Bio.
Posted at 19/11/2022 08:33 by parob
Good post courtesy of Silverfox1963 on lse yesterday:

Simon Thompson places a conservative valuation on HVO of 19p per share but this is just for the core business. He acknowledges that in addition to this there are a number of "hidden balance sheet value" items namely DIM and HVO's share of Imutex and PrEP Bio. He notes rightly that market conditions are not conducive to monetising the value in these assets right now and that it is difficult to value them. Nevertheless "FinnCap has given it a stab, valuing them at £60m, or almost the same as Hvo's entire market cap." This is what excites me. It may take time but the value of these assets is not reflected at all in HVO's share price and one day CF will, I am sure, "surprise and delight" shareholders by monetising these assets.

Posted at 17/11/2022 12:39 by sikhthetech
There you go, as expected...

Beware of the pump and dump..

Look at the trades...lots of small groups of trades within seconds of each other to push the share price higher.

Checkout trmr, byot, nano, sar etc..

1gw's mates use the same tactics, to make it look like there's interest.. they then sell..
Check the posts yourselves.
https://uk.advfn.com/cmn/fbb/thread.php3?id=44682089&from=405


sikhthetech - 14 Nov 2022 - 12:51:46 - 226 of 302 hVIVO plc - HVO
1gw,

Why you haven't commented on trmr's dismal Q3 results? The share price crashed around 30% so far. That follows your usual performance, where your shares crash on facts/results.
Shameful.


Other shares performance as of couple months ago:
https://uk.advfn.com/cmn/fbb/thread.php3?id=49342172&from=4915&to=4915

Posted at 15/11/2022 11:49 by 1gw
Chica1 - On Polb I don't know, just glad to see the rally. Sentiment is a funny thing. I think the newsflow helps, as do JS's upbeat presentations where he points out all that they have done since float. What we don't know is how much work has been going on behind the scenes to woo institutional investors, and that may also be a factor.

My benchmark for POLB is the XBI index. Clearly POLB shareprice moved down broadly in line with XBI until around June which was a bit odd given it had so much of its market cap in cash - and specifically cash that was there to acquire assets, not just fund existing programs. So I thought that all else being equal, it should have moved down at half the pace of the XBI (50% cash at float), or maybe done even better since the market could expect them to pick up distressed biotech assets with their cash, positioning them for any rebound in biotech.

Then POLB underperformed the XBI significantly between around June and end-September. Was that some HVO-heritage investors throwing in the towel when it got down to around 50% float price? Recently it has bounced back spectacularly, and there may well be a bit of momentum investing helping it along now as well as the "fundamental" newsflow.

POLB is biotech, and very small cap at that, so volatility is to be expected. And whatever anyone says about POLB-001 being "likely" to succeed in its trials, these trials are binary outcomes and many a drug has failed a trial that its advocates thought it would pass. If POLB-001 does fail then the shareprice is likely to see a big hit, although the new targets coming out of the AI program mean that the company is likely to be able to build a multi-asset pipeline to insulate itself a bit from individual trial outcomes.

Probably on the wrong thread this, I know, but as many HVO holders are also POLB holders, and HVO has other biotech assets it would like to monetise, I think it's reasonable to post it here.

No advice intended, of course.

Posted at 10/11/2022 11:03 by adorling
Having read the Liberum broker note published after the capital markets day I am more than confident the 21.6p target price they set will be reached in the next 2-3 months given today’s £13.6m RSV Contract win is not included in their numbers.

Also from a technical viewpoint the HVO chart is a textbook BOWL formation and one of the best I have seen in the past 2 years so 40p should be possible in 2023 with several more significant Contracts announced and maybe a Corporate Action or two as well?

Do not let the ignorant shorters on here create doubt in your mind as they will pay a very expensive price for their error of judgement going forward into 2023 as positions are reversed and we get that momentum in share price upwards as they have to “buy to close”. If you are a LTH who has topped up under 10p then there are a definitely a few bags to be made over the 1-3 year timeline IMO.

Hvivo share price data is direct from the London Stock Exchange
Your Recent History
LSE
HVO
Hvivo
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221205 01:23:35